Lamotrigine (Lamictal®)

Selected References:

• Almgren M, et al. 2009. Population-based study of antiepileptic drug exposure in utero–influence on head circumference in newborns. Seizure, 18(10):672-5. 
• Alvarez I, et al. 2025. Breastfed infants exposed to lamotrigine faced a low risk of toxic effects. Acta Paediatr. 114(2):346-354. doi:10.1111/apa.17432 
• American College of Obstetricians and Gynecologists. 2017. Neural tube defects. Practice Bulletin No. 187. Obstet Gynecol  130(6):e279–e290. 
• An K, Xu J, Xi Y, et al. 2026. Analysis of ASMs and male infertility using the FDA adverse event reporting system (FAERS). Front Public Health. 13:1738546. 
• Arfman IJ, et al. 2020. Therapeutic drug monitoring of antiepileptic drugs in women with epilepsy before, during, and after pregnancy. Clin Pharmacokinet, 59(4):427-445.  
• Asranna A, et al. 2018.  Do anti-epileptic drug modifications after first trimester of pregnancy influence fetal malformation or cognitive outcome? Epilepsy Research, 146: 121-125. 
• Ban L, et al.  2015. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLoS One, 10(7): e0131130. 
• Battino D, et al. 2024. Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy. JAMA Neurology. doi:10.1001/jamaneurol.2024.0258. 
• Bech LF, et al. 2018. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. Journal of Neurology, Neurosurgery & Psychiatry, 89(12): 1324-1331. 
• Berry-Noronha A, et al. 2025. Risk of adverse pregnancy outcomes associated with antiseizure medications and their indications: A systematic review and meta-analysis. Neurology. 104(3):e210233.  
• Birnbaum AK, et al. 2020. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurology, 77(4): 441-450. 
• Bjork MH, et al. 2022. Association of prenatal exposure to antiseizure medication with low risk of autism and intellectual disability. JAMA Neurology, 79(7)672-681. 
• Blotière PO, et al. 2019. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology, 93(2):e167-e180. 
• Borthen I. 2015. Obstetrical complications in women with epilepsy. Seizure, 28: 32-34. 
• Bromley RL, et al. 2013. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery & Psychiatry, 84(6): 637-643. 
• Bromley RL, et al. 2018. Fetal antiepileptic drug exposure and cognitive outcomes. Seizure, 44:225–231. 
• Bromley R, et al. 2022. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews, 8(8):CD010224.  
• Bromley RL, et al. 2023. Neurodevelopment of babies born to mothers with epilepsy: a prospective observational cohort study. Epilepsia, 64:2454-2471. 
• Christensen J, et al, 2024. Dreier JW. Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur. 38:100849. 
• Clark CT, Wisner KL. 2018. Treatment of Peripartum Bipolar Disorder. Obstet Gynecol Clin North Am, 45(3):403-417.  
• Cohen‐Israel M, et al. 2018. Short‐and long‐term complications of in utero exposure to lamotrigine. British Journal of Clinical Pharmacology, 84(1): 189-194. 
• Cohen JM, et al. 2019. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. J Clin Psych, 80(4):18m12572.  
• Cohen JM, et al. 2023. Comparative safety of antiseizure medication monotherapy for major malformations. Ann Neurol, 93:551-562.  
• Coste J, et al. 2020. Risk of neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Scientific Reports, 10(1):17362.  
• Couper RG, et al. 2025. Effects of antiseizure medications on sexual hormones and functions in males with epilepsy: A systematic review and meta-analysis. Epilepsia. 66(8):2639-56.  
• Cummings C, et al. 2011. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood, 96(7):643-647. 
• den Besten-Bertholee D, et al, 2025. Mian P. Lamotrigine use in lactating women: Passage into breast milk and infant exposure. Ther Drug Monit. 47(3):317-319.  
• Deshmukh U, et al. 2016. Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine. Neurotoxicol Teratol, 54:5-14. 
• Diav-Citrin O, et al. 2017. Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Res 1,09:1196-1203. 
• Dolk H, et al. 2008. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology, 71:714-722. 
• Dolk H, et al. 2016. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology, 86(18):1716-1725. 
• Dreier JW, et al. 2023. Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders. JAMA Neurology, 80(6):568-577. 
• Dudukina E, et al. 2023. Prenatal exposure to pregabalin, birth outcomes and neurodevelopment – a population-based study in four Nordic countries. Drug Safety, 46;661-675.  
• Fantaneau TA, et al. 2023. Real-world practices for the care of women with epilepsy during pregnancy: a Canadian perspective. Epilepsy and Behavior, 148:109468.  
• Gerard EE, et al. 2015. An update on maternal use of antiepileptic medications in pregnancy and neurodevelopment outcomes. Journal of Pediatric Genetics, 4(2):94-110. 
• Gómez-Ramiro M, et al. 2019. Adverse outcomes during pregnancy and major congenital malformations in infants of patients with bipolar and schizoaffective disorders treated with antiepileptic drugs: a systematic review. Psychiatr Pol, 53(2):223-244. 
• Harden CL, et al. 2009. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology, 73:142–149.  
• Hernandez-Diaz S, et al. 2017. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol, 82(3):457-465.  
• Hernandez-Diaz S, et al. 2025. Use of antiseizure medications early in pregnancy and the risk of major malformations in the newborn. Neurology. 105(3):e213786.  
• Herzog AG, 2008. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure, 17(2):101-110. 
• Hoeltzenbein M, et al. 2024. Antiepileptic treatment with levetiracetam during the first trimester and pregnancy outcome: an observational study. Epilepsia, 65(1):26-36.    
• Holmes LB, et al. 2011. Fetal effects of anticonvulsant polytherapies. Arch Neurol, 68(10):1275-1281. 
• Huber-Mollema Y, et al. 2020. Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology, 267:1724-1736.  
• Huber-Mollema Y, et al. 2019. Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. Epilepsia, 60:1069-1082.  
• Husebye ES, et al. 2018. Verbal abilities in children of mothers with epilepsy: association to maternal folate status. Neurology, 91:e811-21. 
• Jazayeri D, et al. 2018. Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure, 56: 111-114. 
• Kacirova I, et al. 2019. A short communication: lamotrigine levels in milk, mothers, and breastfed infants during the first postnatal month. Therapeutic Drug Monitoring, 41(3):401-404. 
• Kacirova I, et al. 2022. Monitoring of lamotrigine concentrations in mothers, colostrum, and breastfed newborns during the early postpartum period. Biomedicine and Pharmacolotherapy, 151:113167.  
• Khan SJ, et al. 2016. Bipolar disorder in pregnancy and postpartum: principles of management. Curr Psychiatry Rep, 18(2):13.  
• Kohn E, et al. 2022. Magnitude of lamotrigine exposure through breastfeeding. Breastfeeding Medicine, 17(4):341-348.  
• Kuang H, et al. 2024. Reproductive and fetal outcomes in women with epilepsy: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 37(1):2351196. 
• Kuczynska J, et al. 2019. Comparison of plasma, saliva, and hair lamotrigine concentrations. Clinical Biochemistry. 74:24-30. 
• Laspro M, et al. 2025. Association of commonly prescribed antepartum medications and incidence of orofacial Clefting. Cleft Palate Craniofac J. 62(7):1164-74 
• Larcin L, et al. 2024. Real-world assessment of psychotropic and antiepileptic drug use during pregnancy in Belgium: Trends, predictors, and comparative risk of congenital anomalies (2010-2016). Pharmacoepidemiol Drug Saf. 33(10):e70021.  
• Leutritz AL, et al. 2022. Psychotropic medication in pregnancy and lactation and development of exposed children. Br J Clin Pharmacol, 89(2):737-750.  
• Li X, et al. 2024. Drug-associated congenital anomalies of the external ear identified in the United States food and drug administration adverse event reporting system database. Scientific Rep. 14(1):23624. doi:10.1038/s41598-024-74744-3 
• Li Y, Meador KJ. 2022. Epilepsy and pregnancy. Continuum (Minneap Minn), 28(1):34-54.  
• MacEachern DB, et al. 2019. Infertility, impaired fecundity, and live birth/pregnancy ratio in women with epilepsy in the USA: findings of the Epilepsy Birth Control Registry. Epilepsia, 60(9):1993-1998. 
• McVearry KM, et al. 2009. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav, 16(4):609-616. 
• Meador K, et al. 2011. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain, 134:396-404. 
• Meador KJ, et al. 2014. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr, 168(8):729-736.  
• Meador KJ, et al. 2025. Neuropsychological outcomes in 6-year-old children of women with epilepsy: A prospective nonrandomized clinical trial. JAMA Neurology. 82(1):30-39.  
• Meng Q, et al. 2026. Prenatal exposure to antiseizure medications and risk of autism spectrum disorder in offspring: an integrated pharmacovigilance and two-sample mendelian randomization study. Epilepsy Res. 222:107756.  
• Montouris G, et al. 2005. Reproductive and sexual dysfunction in men with epilepsy. Epilepsy & Behavior, 7:7-14. 
• Mostacci B, et al. 2018. Emilia-Romagna study on pregnancy and exposure to antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health. J Neurol Neurosurg Psychiatry, 89:983–988. 
• Newport DJ, et al. 2008. Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics, 122(1):e223-231. 
• Nordmo E, et al. 2009. Severe apnea in an infant exposed to lamotrigine in breast milk. Ann Pharmacother, 43:1893-1897. 
• Ohman I, et al. 2000. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia, 41:709-713. 
• Pack AM, et al. 2025. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication. Epilepsy curr. 15357597241258514.
• Pariente G, et al. 2017. Pregnancy outcomes following in utero exposure to lamotrigine: a systematic review and meta-analysis. CNS Drugs, (6):439-450. 
• Paulzen M, et al. 2015. Lamotrigine in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. Int Clin Psychopharmacol, 30(5):249-254. 
• Pekoz MT, et al. Birth outcomes in pregnant women with epilepsy: A nationwide multicenter study from Türkiye. Epilepsia, 64:2310-2321.  
• Prakash C, et al. 2016. Maternal and fetal outcomes after lamotrigine use in pregnancy: a retrospective analysis from an urban maternal mental health centre in New Zealand. Psychopharmacol Bull, 46(2):63-69. 
• Razaz N, et al. 2017. Association between pregnancy and perinatal outcomes among women with epilepsy. JAMA Neurology, 74(8):983-991. 
• Ren T, et al. 2023. Prenatal carbamazepine exposure and academic performance in adolescents: a population-based cohort study. Neurology, 100(7):e728-e738.  
• Richards N, et al. 2019. Developmental outcomes at age four following maternal antiepileptic drug use. Epilepsy & Behavior, 93:73-79. 
• Rihtman T, et al. 2013. Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function. Reprod Toxicol, 41:115–125. 
• Semet M, et al. 2017. The impact of drugs on male fertility: a review. Andrology, 5(4):640-663. 
• Schmidt CT, et al. 2023. Transfer of anticonvulsants and lithium into amniotic fluid, umbilical cord blood & breast milk: a systematic review & combined analysis. Prog Neuropsychopharmacol Biol Psychiatry, 124:110733.  
• Shi X, et al. 2022. Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: an observation study in northwest China. Epilepsy Behav, 135:108904.  
• Stjerna S, et al. 2024. Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol. Epilepsy Behav. 159:110024.  
• Thomas SV, et al. 2017. Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia, 58:274–281. 
• Thomas SV, et al. 2022. Differential impact of antenatal exposure to antiseizure medications on motor and mental development in infants of women with epilepsy. Discord, 24(3):531-540.  
• Tomson T, et al. 2011. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol, 10(7):609-617. 
• Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet neurol, 17(6):530-538. 
• Tomson T, et al. 2019. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology, 93(9):e831-e840. 
• Vajda FJ, et al. 2013. Lamotrigine in epilepsy, pregnancy and psychiatry–a drug for all seasons? Journal of Clinical Neuroscience. 20(1):13-16. 
• Vajda FJ, et al. 2019. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure, 65:6-11. 
• Vajda F, et al. 2025. Balancing foetal disadvantage and seizure freedom in women capable of pregnancy – the Australian pregnancy register experience. Epilepsy Behav. 172:110663. 
• Vajda FJ, et al. 2025. Is lamotrigine a teratogen? Seizure. 126:1-5. doi:10.1016/j.seizure.2025.01.019 
• Vajda FJE, et al. 2026. Lamotrigine as an antiseizure medication in pregnancy. Seizure. 136:18-22.  
• Veiby G, et al. 2013. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol, 70:1367-1374. 
• Veiby G, et al. 2015. Epilepsy and recommendations for breastfeeding. Seizure, 28:57-65. 
• Velez-Ruiz NJ, et al. 2015. Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Safety, 38(3): 271-278. 
• Veroniki AA, et al. 2017. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Medicine, 15(1):95. 
• Vieta E, et al. Lamotrigine efficacy, safety, and tolerability for women of childbearing age with bipolar disorder: meta-analysis from four randomized, placebo-controlled maintenance studies. European Neuropsychopharmacology, 78:81-92.   
• Wakil L, et al. 2009. Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. Psychopharmacol Bullb 42:91-98. 
• Wang E, et al. 2025. Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: A systematic review and network meta-analysis of congenital malformations and prenatal outcomes. CNS Drugs. 39(1):1-22 
• Wang Q, et al. 2024. Investigation of spontaneous abortion and stillbirth adverse events in epilepsy patients treated with levetiracetam: A pharmacovigilance study. Epilepsy Behav. 160:110077.  
• Wiggs KK, et al. 2020. Antiseizure medication use during pregnancy and risk of ASD and ADHD in children. Neurology, 95;e3232-e3240.  
• Yeh TC, et al. 2021. Bipolar women’s antepartum psychotropic exposure and offspring risk of attention-deficit/hyperactivity disorder and autism spectrum disorder. Journal of Affective Disorders, 295:1407-1414.  
• Zeng Y, et al. 2025. Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting system. J Neurol. 272(6):429.  
• Zhao ZL, et al. 2025. Maternal exposure to lamotrigine and the risk of orofacial clefts in offspring: A systematic review and meta-analysis. Seizure. 131:67-72. doi:10.1016/j.seizure.2025.06.005.